fbpx

Category

Lundbeckfonden Ventures
After Discussions with FDA, NDA Submission Planned for 3Q 2020 under Accelerated Approval Pathway  Reltecimod in conjunction with currently available standard of care demonstrated a significant difference in the percentage of patients who achieved resolution of organ dysfunction/failure by Day 14 versus standard of care alone  Resolution of organ dysfunction/failure at Day 14...
Financing co-led by Ysios Capital and INKEF Capital, joined by Lundbeckfonden Ventures, LSP, and existing investors BioGeneration Ventures and InnovationQuarter • Proceeds to be used to achieve clinical proof of concept for lead compound, VMX-C001, advance program to registrational studies, accelerate manufacturing trajectory towards commercial scale, and advance the discovery platform program Leiden, The Netherlands,...
BURLINGTON, Mass. – July 1, 2020 – scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it has resubmitted its 505(b)(2) New Drug Application (NDA) to the U.S. Food and...
Acacia Pharma Announces US FDA Approval of BYFAVO™ (remimazolam) for injection for the Induction and Maintenance of Procedural Sedation   BYFAVO is a very rapid onset/offset IV benzodiazepine sedative for use during invasive medical procedures lasting 30 minutes or less, such as colonoscopy and bronchoscopy Approximately 25 million such procedures take place annually in the...
Lead ‘OncoMimics’ candidate EO2401 planned to start first clinical trials for Glioblastoma and Adrenal Tumors during mid-2020 Paris, France and Cambridge, MA, USA – June 25, 2020 ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge  of the microbiome-immunoinflammation axis to develop next-generation therapeutics, today announces a new financing totaling €46.3 million ($52.6million) to...
SNF472 selectively inhibits pathological calcification by binding to hydroxyapatite crystals Palma, Spain and San Diego, USA, 25 June 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, today announced that data examining the mechanism of action of SNF472, Sanifit’s lead compound in development, has been published in the British Journal of...
Newly appointed VP of Business Development and SVP of Clinical Development each bring to Sanifit over 20 years of industry experience Palma, Spain and San Diego, USA, 01 June 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, is delighted to announce two new appointments to its Executive leadership team, with...
Cambridge, UK and Indianapolis, US –  1 June 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a commercial-stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures or chemotherapy, announces an amendment to the terms...
Cambridge, UK and Indianapolis, US – 8 May 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces...
Cambridge, UK and Indianapolis, US – 7 May 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces...
1 2 3 59

Nyheder

Fem unge medicinstuderende på forskningsophold i USA
9. juli 2020
Lundbeckfonden Ventures investerer i antidot mod blodfortyndere
8. juli 2020
Erfaren hjerneforsker i spidsen for The Brain Prize
30. juni 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge